Osteocalcin (OCN), a non-collagenous protein synthesized by osteoblasts, is integral to bone mineralization and demonstrates significant effects on metabolic and neurological functions. Its undercarboxylated form, Glu-OCN, has emerged as a key regulator of glucose metabolism in diabetes, bone density in osteoporosis (OP), and lipid metabolism in conditions such as nonalcoholic fatty liver disease (NAFLD). Additionally, Glu-OCN is implicated in neurodegenerative and cardiovascular diseases through its roles in neurotransmitter synthesis and vascular calcification, respectively. This review examines the essential functions of Glu-OCN in the management of metabolic and neurodegenerative disorders, emphasizing its significance as both a diagnostic biomarker and therapeutic target. While findings to date are promising, most studies remain observational. Advanced detection methodologies and extensive longitudinal studies are urgently needed to elucidate the mechanisms and clinical applications of Glu-OCN. Advancements in this area could facilitate the integration of Glu-OCN into personalized medicine approaches, improving early diagnosis, risk assessment, and treatment monitoring.

Researchers at the Johns Hopkins Kimmel Cancer Center, Johns Hopkins All Children’s Hospital and four other institutions have devised a novel method to test for prostate cancer using biomarkers present in urine, funded in part by the National Institutes of Health. This approach could significantly reduce the need for invasive, often painful biopsies, they say.

A new policy review published in The Lancet Oncology and led by Ian Tannock and Madeline Pe, together with an international team of oncologists, statisticians, patients and patient-reported outcomes (PRO) experts from Common Sense Oncology (CSO) and the European Organisation for Research and Treatment of Cancer (EORTC), emphasises the critical role of health-related quality of life (HRQoL) data in the evaluation of treatments for people with advanced cancer. This publication highlights the importance of having standardised responder criteria when evaluating HRQoL in clinical trials to improve patient care and clinical decision-making.

Engineers at Duke University have developed a wireless patch that can non-invasively measure skin and tissue stiffness at depths of up to a couple of inches. Already smaller than a smartwatch, the device could be a gateway into a wide array of medical applications such as the monitoring of wound healing, chronic conditions like skin cancer, fluid management during resuscitation efforts and muscle rehabilitation.

Even as policymakers have made it much easier to prescribe buprenorphine for opioid addiction, most pharmacies still aren’t carrying the treatment.